Ligelizumab for Chronic Spontaneous Urticaria*
British journal of dermatology/British journal of dermatology, Supplement（2020）
Abstract
Chronic spontaneous urticaria (CSU) is a very disabling condition. It can be difficult to treat. Less than 50% of people respond to licenced dosages of H1-antihistamines (though up-dosing where safe increases the response rate). Additionally, only a small proportion respond to the addition of the leukotriene receptor antagonist (LTRA) montelukast.1,2.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined